BioMérieux SA 2022 Universal Registration Document

The report highlights bioMérieux's commitment to public health and its efforts to combat antimicrobial resistance, sepsis, and emerging pathogens. The company acquired Specific Diagnostics, launched a new syndromic testing system, BIOFIRE® SPOTFIRE®, and made progress on its antimicrobial stewardship program. bioMérieux also continued to expand its global presence, investing in new production facilities and acquiring companies. The report details the company's progress on its environmental, social, and governance (ESG) goals.